One step closer to the new frontiers of healthcare for cardiomyopathy patients There were great advances in the treatment of heart failure (HF) over the past decades, characterised by the inclusion of ARNI and SGLT2 inhibitors in the latest guidelines. The use of cardiac myosin inhibitors specifically for patients with hypertrophic cardiomyopathy (HCM) is also making large steps forward, which reflects the next step towards more personalised treatment.

Roles for cardiologists in government, research councils and regulatory sectors Clinicians have numerous opportunities to gain experience in governmental or regulatory organisations, including health technology assessment bodies and payors. These organisations often seek advice from individuals with clinical experience and knowledge, and they increasingly engage with the clinical community on a regular basis. Cardiologists can also take on formal advisory roles, either through working groups or ad hoc and standing committees. Additionally, there may be part-time or full-time employment opportunities available, often providing leadership in research councils.

HFA CONFERENCE NEWS June 29 - July 01, 2021, Virtual IV Iron Can Save Costs in HF With Iron Deficiency in Analysis; HF Med Undertreatment Due to Older Age Common, Flouts Evidence; Iron-Clad Benefits of CRT Seen in Reduced-EF Heart Failure; Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes

"COVID-19 and cardiovascular diseases: main aspects" The report of Igor S. Yavelov MD, PhD, Professor of cardiology CV risk factors and CVD are present in many patients with COVID-19 and their presence is associated with an increased risk of cardiovascular complications with new coronavirus infection.

Young adults who lost and then restored heart health had lower risk of heart attack, stroke A long-term analysis of young adults in Korea found that those with poor heart health had higher rates of cardiovascular disease at a younger age.

EAS Helsinki 2021 Virtual. THE RISE OF CARDIOMETABOLIC DISEASE Not only are we living in a COVID-19 pandemic, but also an accelerating pandemic of cardiometabolic disease, requiring renewed focus. The third plenary session discussed options to address this escalation in cardiometabolic disease.

COVID-19 vaccine benefits still outweigh risks, despite possible rare heart complications. Statement from the American Heart Association/American Stroke Association Late last week, the U.S. Centers for Disease Control and Prevention (CDC) alerted health care professionals that they are monitoring the Vaccine Adverse Events Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) for cases of young adults developing the rare heart-related complication myocarditis, after receiving a COVID-19 vaccine manufactured by Pfizer-BioNTech or Moderna.

Administration of patients during and after a coronavirus pandemic. Interview with professor Mekhman N. Mamedov. Dear Colleagues! On April 27, 2021, at the initiative of the Indonesian Society of Cardiology, an online meeting was held with one of the leading experts of Russia in the cardiology, Professor Mekhman N. Mamedov

Foundation for promotion cardiology

Six pregnancy complications are among red flags for heart disease later in life. American Heart Association Scientific Statement Six pregnancy-related complications - high blood pressure, gestational diabetes, preterm delivery, small-for-gestational-age delivery, pregnancy loss or placental abruption – increase a woman’s risk for developing cardiovascular disease (CVD) later in life, according to a new scientific statement from the American Heart Association, published today in the Association’s flagship journal Circulation.